{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:10:15Z","timestamp":1790187015000,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012533","name":"Minia University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012533","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For over 3.5\u00a0years, SARS CoV-2 is continuing to evolve threatening to return all and any improvement the world has made into square one. In this clinically oriented systematic review and perspective, the author explains how the best current medical evidence is strongly supporting the use of the low cost, widely available and very safe nitazoxanide in early management of COVID-19, debates the relevant theoretical studies that negated or doubted this benefit, and suggests an African roadmap to preempt the worst-case scenario if or when a new SARS CoV-2 (sub) variant or even a new respiratory virus causes a new global surge of morbidity and mortality. Kelleni\u2019s protocol, including nitazoxanide as an integral component, is continuing to perfectly save lives of patients infected with many viruses, including SARS CoV-2 and the author stresses that respiratory RNA viruses are best managed with early pharmacological treatment. Broad-spectrum antimicrobials as nitazoxanide and azithromycin together with other therapeutics as non-steroidal anti-inflammatory drugs and the antihistaminic loratadine should be considered first to personalize the clinical management of COVID-19 and selected other alarming viral infections.<\/jats:p>","DOI":"10.1007\/s10787-023-01263-4","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T10:01:36Z","timestamp":1686909696000},"page":"3335-3338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The African Kelleni\u2019s roadmap using nitazoxanide and broad-spectrum antimicrobials to abort returning to COVID-19 square one"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6290-6025","authenticated-orcid":false,"given":"Mina T.","family":"Kelleni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"1263_CR1","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40261-022-01213-y","volume":"42","author":"M Abuelazm","year":"2022","unstructured":"Abuelazm M, Ghanem A, Awad AK, Farahat RA, Labieb F, Katamesh BE, Abdelazeem B (2022) The effect of nitazoxanide on the clinical outcomes in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig 42:1031\u20131047","journal-title":"Clin Drug Investig"},{"key":"1263_CR2","doi-asserted-by":"publisher","first-page":"11169","DOI":"10.1007\/s11033-022-07822-2","volume":"49","author":"HM Al-kuraishy","year":"2022","unstructured":"Al-kuraishy HM, Al-Gareeb AI, Elekhnawy E, Batiha GE-S (2022) Nitazoxanide and COVID-19: a review. Mol Biol Rep 49:11169\u201311176","journal-title":"Mol Biol Rep"},{"key":"1263_CR3","doi-asserted-by":"publisher","first-page":"100981","DOI":"10.1016\/j.eclinm.2021.100981","volume":"37","author":"VF Blum","year":"2021","unstructured":"Blum VF, Cimerman S, Hunter JR, Tierno P, Lacerda A, Soeiro A, Cardoso F, Bellei NC, Maricato J, Mantovani N, Vassao M, Dias D, Galinskas J, Janini LMR, Santos-Oliveira JR, Da-Cruz AM, Diaz RS (2021) Nitazoxanide superiority to placebo to treat moderate COVID-19\u2014a pilot prove of concept randomized double-blind clinical trial. eClinicalMedicine 37:100981","journal-title":"eClinicalMedicine"},{"key":"1263_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2020.100011","volume":"2","author":"A Firth","year":"2021","unstructured":"Firth A, Prathapan P (2021) Broad-spectrum therapeutics: a new antimicrobial class. Curr Res Pharmacol Drug Discov 2:100011","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"1263_CR5","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s10787-020-00755-x","volume":"28","author":"MT Kelleni","year":"2020","unstructured":"Kelleni MT (2020a) ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror. Inflammopharmacology 28:1477\u20131480","journal-title":"Inflammopharmacology"},{"key":"1263_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104874","volume":"157","author":"MT Kelleni","year":"2020","unstructured":"Kelleni MT (2020b) Nitazoxanide\/azithromycin combination for COVID-19: a suggested new protocol for early management. Pharmacol Res 157:104874","journal-title":"Pharmacol Res"},{"key":"1263_CR7","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1080\/21645515.2021.1885281","volume":"17","author":"MT Kelleni","year":"2021","unstructured":"Kelleni MT (2021a) BCG vaccination potential for COVID-19: an analytical approach. Hum Vaccin Immunother 17:2448\u20132450","journal-title":"Hum Vaccin Immunother"},{"key":"1263_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s12026-021-09219-y","volume":"69","author":"MT Kelleni","year":"2021","unstructured":"Kelleni MT (2021b) COVID-19, Ebola virus disease, and Nipah virus infection reclassification as novel acute immune dysrhythmia syndrome (n-AIDS): potential crucial role for immunomodulators. Immunol Res 69:457\u2013460","journal-title":"Immunol Res"},{"key":"1263_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110982","volume":"133","author":"MT Kelleni","year":"2021","unstructured":"Kelleni MT (2021c) Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomed Pharmacother 133:110982","journal-title":"Biomed Pharmacother"},{"key":"1263_CR10","first-page":"121","volume":"3","author":"MT Kelleni","year":"2021","unstructured":"Kelleni MT (2021d) NSAIDs\/nitazoxanide\/azithromycin immunomodulatory protocol used in adult, geriatric, pediatric, pregnant, and immunocompromised COVID-19 patients: a real-world experience. Can J Med 3:121\u2013143","journal-title":"Can J Med"},{"key":"1263_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.19080\/IJOPRS.2021.05.555658","volume":"5","author":"MT Kelleni","year":"2021","unstructured":"Kelleni MT (2021e) SARS CoV-2 vaccination autoimmunity, antibody dependent covid-19 enhancement and other potential risks: beneath the tip of the iceberg. Int J Pulm Respir Sci 5:1\u201352. https:\/\/doi.org\/10.19080\/IJOPRS.2021.05.555658","journal-title":"Int J Pulm Respir Sci"},{"key":"1263_CR12","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s42399-021-00824-4","volume":"3","author":"MT Kelleni","year":"2021","unstructured":"Kelleni MT (2021f) Tocilizumab, remdesivir, favipiravir, and dexamethasone repurposed for COVID-19: a comprehensive clinical and pharmacovigilant reassessment. SN Compr Clin Med 3:919\u2013923","journal-title":"SN Compr Clin Med"},{"key":"1263_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10787-021-00896-7","volume":"30","author":"MT Kelleni","year":"2022","unstructured":"Kelleni MT (2022a) NSAIDs and Kelleni\u2019s protocol as potential early COVID-19 treatment game changer: could it be the final countdown? Inflammopharmacology 30:343\u2013348","journal-title":"Inflammopharmacology"},{"key":"1263_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/14787210.2021.1939683","volume":"20","author":"MT Kelleni","year":"2022","unstructured":"Kelleni MT (2022b) NSAIDs\/nitazoxanide\/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects. Expert Rev Anti Infect Ther 20:17\u201321","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1263_CR15","doi-asserted-by":"crossref","unstructured":"Kelleni MT (2022c) Personalized expanded Kelleni\u2019s immunomodulatory COVID-19 protocol safely used to manage severe COVID-22: a case-report. OSF (preprint) 1031219\/osfio\/ysfr2","DOI":"10.31219\/osf.io\/ysfr2"},{"key":"1263_CR16","doi-asserted-by":"crossref","unstructured":"Kelleni MT (2022d) Repurposing bcg vaccine to protect my parents, children, and my family against COVID-19: a real-life experience. OSF (preprint) 1031219\/osfio\/z2qw6","DOI":"10.31219\/osf.io\/z2qw6"},{"key":"1263_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jinf.2023.01.027","volume":"86","author":"MT Kelleni","year":"2023","unstructured":"Kelleni MT (2023a) Evolution of SARS CoV-2 Omicron subvariants BF.7 and XBB.1.5: time to follow Africa and abort all COVID restrictions. J Infect 86:405","journal-title":"J Infect"},{"key":"1263_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jinf.2022.12.007","volume":"86","author":"MT Kelleni","year":"2023","unstructured":"Kelleni MT (2023b) Real-life practice of the Egyptian Kelleni\u2019s protocol in the current tripledemic: COVID-19, RSV and influenza. J Infect 86:154\u2013225","journal-title":"J Infect"},{"key":"1263_CR19","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s10787-023-01180-6","volume":"31","author":"MT Kelleni","year":"2023","unstructured":"Kelleni MT (2023c) Real-world practice of the Egyptian Kelleni\u2019s protocol amid changing tropism of SARS-CoV-2 omicron BA.5.2.1.7, XBB 1.5 and CH1.1 subvariants: a multi-purpose protocol. Inflammopharmacology 31:1551\u20131560","journal-title":"Inflammopharmacology"},{"key":"1263_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2023.03.018","author":"MT Kelleni","year":"2023","unstructured":"Kelleni MT (2023d) SARS CoV-2 genetic jump to a new SARS CoV-3 pandemic: let\u2019s be prepared. J Infect. https:\/\/doi.org\/10.1016\/j.jinf.2023.03.018","journal-title":"J Infect"},{"key":"1263_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173748","volume":"891","author":"AS Lokhande","year":"2021","unstructured":"Lokhande AS, Devarajan PV (2021) A review on possible mechanistic insights of nitazoxanide for repurposing in COVID-19. Eur J Pharmacol 891:173748","journal-title":"Eur J Pharmacol"},{"key":"1263_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s43141-020-00055-5","volume":"18","author":"DB Mahmoud","year":"2020","unstructured":"Mahmoud DB, Shitu Z, Mostafa A (2020) Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19? J Genet Eng Biotechnol 18:35","journal-title":"J Genet Eng Biotechnol"},{"key":"1263_CR23","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00228-022-03380-5","volume":"78","author":"PR Martins-Filho","year":"2022","unstructured":"Martins-Filho PR, do Nascimento-Junior EM, Barreto-Alves JA, Fakhouri R, Ferreira LC (2022) Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. Eur J Clin Pharmacol 78:1813\u20131821","journal-title":"Eur J Clin Pharmacol"},{"key":"1263_CR24","doi-asserted-by":"publisher","first-page":"2003725","DOI":"10.1183\/13993003.03725-2020","volume":"58","author":"RMR Patricia","year":"2021","unstructured":"Patricia RMR, Pedro LS, Fernanda FC, Marco Antonio CM-J, Paulo FGMMT, Marcos AM, Lu\u00eds Frederico GDO, Cristiano CL, Ezequiel ADS, Walter FJ, Ana Paula SMF, Kleber GF, Erick M, Nara FdM, Jos\u00e9 M\u00e1rio JG, Melanie NC, Ivonise SDS, Nat\u00e1lia FP, Paula VMM, Raissa PR, Alex FdC, Pedro Augusto A, Jos\u00e9 Luiz P-M, Artur TC, Daniela BBT, Rafael EM, Ronir RL, Paolo P, Lapa E Silva JR (2021) Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. Eur Respir J 58:2003725","journal-title":"Eur Respir J"},{"key":"1263_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2022.100120","volume":"14","author":"P Prathapan","year":"2022","unstructured":"Prathapan P (2022) A determination of pan-pathogen antimicrobials? Med Drug Discov 14:100120","journal-title":"Med Drug Discov"},{"key":"1263_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.7326\/M22-2249","volume":"176","author":"A Qaseem","year":"2022","unstructured":"Qaseem A, Yost J, Miller MC, Andrews R, Jokela JA, Forciea MA, Abraham GM, Humphrey LL (2022) Outpatient treatment of confirmed COVID-19: living, rapid practice points from the American College of Physicians (version 1). Ann Intern Med 176:115\u2013124","journal-title":"Ann Intern Med"},{"key":"1263_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.844728","volume":"9","author":"PRM Rocco","year":"2022","unstructured":"Rocco PRM, Silva PL, Cruz FF, Tierno P, Rabello E, Junior JC, Haag F, de Avila RE, da Silva JDG, Mamede MMS, Buchele KS, Barbosa LCV, Cabral AC, Junqueira AAF, Araujo-Filho JA, da Costa L, Alvarenga PPM, Moura AS, Carajeleascow R, de Oliveira MC, Silva RGF, Soares CRP, Fernandes A, Fonseca FG, Camargos VN, Reis JS, Franchini KG, Luiz RR, Morais S, Sverdloff C, Martins CM, Felix NS, Mattos-Silva P, Nogueira CMB, Caldeira DAF, Pelosi P, Lapa ESJR (2022) Nitazoxanide in patients hospitalized with COVID-19 pneumonia: a multicentre, randomized, double-blind, placebo-controlled trial. Front Med (lausanne) 9:844728","journal-title":"Front Med (lausanne)"},{"key":"1263_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3855\/jidc.16982","volume":"17","author":"R Romero-Cabello","year":"2023","unstructured":"Romero-Cabello R, Romero-Feregrino R, Romero-Feregrino R, Mu\u00f1oz-Cordero B, Sevilla-Fuentes S (2023) Outpatient treatment of COVID-19: an experience with 552 cases in Mexico. J Infect Dev Ctries 17:311\u2013318","journal-title":"J Infect Dev Ctries"},{"key":"1263_CR29","doi-asserted-by":"publisher","first-page":"101310","DOI":"10.1016\/j.eclinm.2022.101310","volume":"45","author":"J-F Rossignol","year":"2022","unstructured":"Rossignol J-F, Bardin MC, Fulgencio J, Mogelnicki D, Br\u00e9chot C (2022) A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19. eClinicalMedicine 45:101310","journal-title":"eClinicalMedicine"},{"key":"1263_CR30","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.03.21252509","author":"M Silva","year":"2023","unstructured":"Silva M, Espejo A, Pereyra ML, Lynch M, Thompson M, Laborde L, Taconelli H, Patricia P, Pereson MJ, Garbini M, Crucci P and Enriquez D (2023) Efficacy of nitazoxanide in reducing the viral ad in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel-group, pilot study. Med Res Arch. https:\/\/doi.org\/10.1101\/2021.03.03.21252509","journal-title":"Med Res Arch"},{"key":"1263_CR31","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00228-023-03486-4","volume":"79","author":"ES Vaz","year":"2023","unstructured":"Vaz ES, Vassiliades SV, Giarolla J, Polli MC, Parise-Filho R (2023) Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. Eur J Clin Pharmacol 79:723\u2013751","journal-title":"Eur J Clin Pharmacol"},{"key":"1263_CR32","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1080\/14787210.2022.2142117","volume":"20","author":"TC Weng","year":"2022","unstructured":"Weng TC, Weng TS, Lai CC, Chao CM, Wang JH (2022) Clinical outcomes, virological efficacy and safety of nitazoxanide in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther 20:1615\u20131622","journal-title":"Expert Rev Anti Infect Ther"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-023-01263-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-023-01263-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-023-01263-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T14:03:31Z","timestamp":1701525811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-023-01263-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1263"],"URL":"https:\/\/doi.org\/10.1007\/s10787-023-01263-4","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"assertion":[{"value":"18 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}